menu search

IQAIF / IQ-AI notes positive outcomes from recent pediatric brain tumour studies

IQ-AI notes positive outcomes from recent pediatric brain tumour studies
IQ-AI Ltd's (LSE:IQAI, OTCQB:IQAIF) wholly-owned subsidiary Imaging Biometrics has noted the outcomes of two pre-clinical studies at the latest Society of Neuro-Oncology (SNO) Pediatric Conference held in Washington, DC. The studies, led by Dr Mona Al-Gizawiy from the Medical College of Wisconsin, highlighted the inhibitory effects of oral gallium maltolate (GaM) on two types of pediatric brain tumours, namely atypical teratoid rhabdoid tumour (ATRT) and glioblastoma multiforme (GBM). Read More
Posted: Jun 27 2023, 05:21
Author Name: Proactive Investors
Views: 112553

IQAIF News  

IQ-AI higlights use of subsidiary's software in brain cancer study

By Proactive Investors
October 18, 2023

IQ-AI higlights use of subsidiary's software in brain cancer study

IQ-AI has highlighted a new study into a rare form of brain cancer that used subsidiary Imaging  Biometric's dynamic susceptibility contrast (DSC) ma more_horizontal

IQ-AI subsidairy secures second orphan drug designation

By Proactive Investors
October 9, 2023

IQ-AI subsidairy secures second orphan drug designation

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF)'s subsidiary, Imaging Biometrics, has secured orphan drug designation from the US Food and Drug Administration for more_horizontal

IQ-AI hails the latest data on IB Neuro technology

By Proactive Investors
September 8, 2023

IQ-AI hails the latest data on IB Neuro technology

Imaging Biometrics (IB), a subsidiary of IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), has confirmed the effectiveness of its IB Neuro technology for brain scan more_horizontal

IQ-AI to focus on the commercial potential of its software alongside phase I study

By Proactive Investors
August 17, 2023

IQ-AI to focus on the commercial potential of its software alongside phase I study

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) said it aims to convert a significant portion of the 45 sites currently assessing its IB imaging software into clien more_horizontal

IQ-AI subsidiary Imaging Biometric has bone metastases tech selected by Medical College of Wisconsin

By Proactive Investors
July 19, 2023

IQ-AI subsidiary Imaging Biometric has bone metastases tech selected by Medical College of Wisconsin

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF)'s wholly owned subsidiary Imaging Biometrics has had its handheld application IB Nimble selected by the Orthopedic D more_horizontal

IQ AI shares surge following promising subsidiary announcement

By Proactive Investors
July 13, 2023

IQ AI shares surge following promising subsidiary announcement

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) surged in early-Thursday trades following a promising update from its subsidiary Imaging Biometrics. Imaging Biometr more_horizontal

IQ-AI subsidiary wins orphan drug status for pediatric brain tumour treatment

By Proactive Investors
July 13, 2023

IQ-AI subsidiary wins orphan drug status for pediatric brain tumour treatment

Imaging Biometrics, a wholly-owned subsidiary of IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), been has granted orphan drug designation (ODD) status for its oral more_horizontal

IQ-AI sent 4% higher following recent successful pre-clinical studies

By Proactive Investors
June 27, 2023

IQ-AI sent 4% higher following recent successful pre-clinical studies

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), the company focused on delivering imaging platforms to treat patients more effectively, enjoyed a boost on the Lond more_horizontal


Search within

Pages Search Results: